In vitro evaluation of a 'stealth' adenoviral vector for targeted gene delivery to adult mammalian neurones

Journal of Gene Medicine

Volumn 11, Issue 4, 2009, Pages 335-344

  Sims, Karen ^a   Ahmed, Zubair ^a   Read, Martin L ^a   Cooper Charles, Lisa ^a   Gonzalez, Ana Maria ^a   Fisher, Kerry D ^b   Berry, Martin ^a   Seymour, Leonard W ^b   Logan, Ann ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

'Stealth' modification; Adenovirus 5; Neurones; Pinocytosis; Retargeting

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FIBROBLAST GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; NERVE GROWTH FACTOR; POLYMER; VIRUS DNA;

ANIMAL CELL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL TYPE; CONTROLLED STUDY; DRUG COATING; ENDOSOME; FIBROBLAST CULTURE; GENE TARGETING; GLIOMA CELL; IN VITRO STUDY; MALE; MAMMAL CELL; NERVE CELL MEMBRANE; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPORTER GENE; SPINAL GANGLION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; ANIMALS; CELLS, CULTURED; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; GANGLIA, SPINAL; GENE THERAPY; GENETIC VECTORS; GLIOMA; GREEN FLUORESCENT PROTEINS; NERVE GROWTH FACTOR; NEURONS; RATS;

HUMAN ADENOVIRUS TYPE 5; MAMMALIA; MIRIDAE; RATTUS;

EID: 65949112268     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1306     Document Type: Article

References (25)

1. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
2. Chillon M, Lee JH, Fasbender A, Welsh MJ. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther 1998; 5: 995-1002.
3. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005; 11: 66-79.
4. Hofherr SE, Mok H, Gushiken FC, Lopez JA, Barry MA. Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther 2007; 18: 837-848.
5. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther 2008; 16: 1276-1282.
6. Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum Gene Ther 2008.
7. Crowther C, Ely A, Hornby J, et al. Efficient inhibition of hepatitis B virus replication in vivo using PEG-modified adenovirus vectors. Hum Gene Ther 2008.
8. Carlisle RC, Benjamin R, Briggs SS, et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. J Gene Med 2008; 10: 400-411.
9. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8: 341-348.
10. Green NK, Herbert CW, Hale SJ, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004; 11: 1256-1263.
11. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther 2001; 3: 105-112.
12. Gupta V, Wang W, Sosnowski BA, Hofman FM, Chen TC. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells. Neurosurg Focus 2006; 20: E26.
13. Morrison J, Briggs SS, Green N, et al. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol Ther 2008; 16: 244-251.
14. Thoma C, Wieland S, Moradpour D, et al. Ligand-mediated retargeting of recombinant adenovirus for gene transfer in vivo. Gene Ther 2000; 7: 1039-1045.
15. Griffiths G, Back R, Marsh M. A quantitative analysis of the endocytic pathway in baby hamster kidney cells. J Cell Biol 1989; 109: 2703-2720.
16. Sims K, Ahmed Z, Gonzalez AM, et al. Targeting adenoviral transgene expression to neurons. Mol Cell Neurosci 2008; 39: 411-417.
17. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993; 75: 477-486.
18. Green NK, Morrison J, Hale S, et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritonealmodel of human ovarian cancer. Journal of Gene Medicine 2008; 10: 280-289.
19. Tischner K. Uptake of horseradish peroxidase by sensory nerve fibres in vitro. J Anat 1977; 124: 83-97.
20. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1): S152-S163.
21. Oupicky D, Carlisle RC, Seymour LW. Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther 2001; 8: 713-724.
22. Carlisle RC, Etrych T, Briggs SS, Preece JA, Ulbrich K, Seymour LW. Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction. J Gene Med 2004; 6: 337-344.
23. Svensson U. Role of vesicles during adenovirus 2 internalization into HeLa cells. J Virol 1985; 55: 442-449.
24. Meier O, Gastaldelli M, Boucke K, Hemmi S, Greber UF. Early steps of clathrin-mediated endocytosis involved in phagosomal escape of Fcgamma receptor-targeted adenovirus. J Virol 2005; 79: 2604-2613.
25. Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target 2007; 15: 546-551.